⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28410628 | 1.00 | — | — | |
| SCHEMBL2291199 | 0.92 | — | — | |
| SCHEMBL17873075 | 0.74 | — | — | |
| SCHEMBL2573506 | 0.72 | — | — | |
| SCHEMBL10007356 | 0.72 | — | — | |
| SCHEMBL12956570 | 0.72 | — | — | |
| SCHEMBL575060 | 0.69 | — | — | |
| SCHEMBL4582480 | 0.67 | — | — | |
| SCHEMBL989793 | 0.66 | — | — | |
| SCHEMBL13564550 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220640-A1 | CDK PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-11-16 | — | — | WO | claimed |
| EP-0322242-B1 | Adenosine derivatives | GLAXO GROUP LTD (GB) | 1998-04-01 | — | — | EP | claimed |
| CN-1024198-C | Adenosine derivatives and their preparation | GLAXO GROUP LTD (GB) | 1994-04-13 | — | — | CN | claimed |
| US-5032583-A | Cardiovascular disorders | GLAXO GROUP LIMITED (GB) | 1991-07-16 | — | — | US | claimed |
| CN-1035295-A | Adenosine derivative | GLAXO GROUP LTD (GB) | 1989-09-06 | — | — | CN | claimed |
| EP-0322242-A2 | Adenosine derivatives | GLAXO GROUP LIMITED (GB) | 1989-06-28 | — | — | EP | claimed |
| WO-2023220640-A1 | CDK PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-4251613-A1 | AMINOHETEROARYL KINASE INHIBITORS | Allorion Therapeutics Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| US-11384083-B2 | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors | INCYTE CORPORATION (US) | 2022-07-12 | — | — | US | disclosed |
| WO-2022111621-A1 | AMINOHETEROARYL KINASE INHIBITORS | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2022-06-02 | — | — | WO | disclosed |
| WO-2021249258-A1 | DEUTERATED PYRIDOPYRIMIDINONES AND THEIR USE AS HIGHLY SELECTIVE CYCLIN-DEPENDENT KINASE 2 INHIBITORS | ZENTAUR THERAPEUTICS INTERNATIONAL LIMITED (CN) | 2021-12-16 | — | — | WO | disclosed |
| US-20200392139-A1 | PYRROLO[2,3-D]PYRIMIDINONE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2020-12-17 | — | — | US | disclosed |
| WO-2020168197-A1 | PYRROLO[2,3-D]PYRIMIDINONE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION (US) | 2020-08-20 | — | — | WO | disclosed |
| EP-2143709-A1 | AMIDE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2010-01-13 | — | — | EP | disclosed |
| WO-2009152027-A1 | 5,7-DIHYDRO-6H-PYRROLO[2,3-D]PYRIMIDIN-6-ONE DERIVATIVES FOR MARK INHIBITION | MERCK & CO., INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| EP-0322242-B1 | Adenosine derivatives | GLAXO GROUP LTD (GB) | 1998-04-01 | — | — | EP | disclosed |
| CN-1024198-C | Adenosine derivatives and their preparation | GLAXO GROUP LTD (GB) | 1994-04-13 | — | — | CN | disclosed |
| US-5032583-A | Cardiovascular disorders | GLAXO GROUP LIMITED (GB) | 1991-07-16 | — | — | US | disclosed |
| CN-1035295-A | Adenosine derivative | GLAXO GROUP LTD (GB) | 1989-09-06 | — | — | CN | disclosed |
| EP-0322242-A2 | Adenosine derivatives | GLAXO GROUP LIMITED (GB) | 1989-06-28 | — | — | EP | disclosed |